Critical Reviews in Oncology Hematology

Article	Citations
Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting	373
Stereotactic body radiation therapy versus conventional external beam radiation therapy for painful bone metastases: A systematic review and meta-analysis of randomized trials	242
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm	155
Letter to the Editor regarding the article “A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs app	119
Comparative efficacy of first-line therapies for PD-L1-negative advanced NSCLC: A network meta-analysis with reconstructed survival curves	114
From immunohistochemistry to machine learning-based patient stratification by tumour proliferation characteristics in head and neck cancer	87
Beyond the blood-brain barrier: Intranasal vaccines in cancer immunotherapy	87
Direct and indirect effects on child neurocognitive development when maternal cancer is diagnosed during pregnancy: What do we know so far?	86
Advancing tumor vaccines: Overcoming TME challenges, delivery strategies, and biomaterial-based vaccine for enhanced immunotherapy	85
Real-world analysis of primary central nervous system diffuse large B-cell lymphoma	81
A systematic review and meta-analysis of blood-based biomarkers in anal squamous cell cancer treated with chemoradiotherapy	68
Harnessing tumor metabolism during cancer treatment: A narrative review of emerging dietary approaches	66
A non-invasive miRNA-based approach in early diagnosis and therapeutics of oral cancer	66
Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system	65
When immunity backfires: Meta-analysis on sarcoidosis reactivation in cancer patients treated with immune checkpoint inhibitors	64
Navigating management of localized prostate cancer in the geriatric population	61
Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice	59
Dysregulation of systemic immunity in colorectal cancer and its clinical applications as biomarkers and therapeutics	59
Cytokine-based NK cell engineering for cancer immunotherapy	58
Salivary phosphate: A promising non-invasive biomarker for oral and systemic disease screening	53
Unveiling the Role of JAK2/STAT3 signaling in chemoresistance of gynecological cancers: From mechanisms to therapeutic implications	52
The role of cGAS-STING in remodeling the tumor immune microenvironment induced by radiotherapy	51
Skin barrier dysfunction in cutaneous T-cell lymphoma: From pathogenic mechanism of barrier damage to treatment	51
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II	48
Beyond monospecificity: The modular revolution of bispecific immunotherapeutics	48

Development of treatment strategies for advanced HER2-positive gastric cancer: Insights from clinical trials	47
Systemic immune-inflammation index as a predictor of survival in non-small cell lung cancer patients undergoing immune checkpoint inhibition: A systematic review and meta-analysis	46
Microbiome and lung cancer: carcinogenic mechanisms, early cancer diagnosis, and promising microbial therapies	45
Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): ‘Where the streets have no name’	45
Novel insight into the Warburg effect: Sweet temptation	44
Targeted doublet therapy with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer: A systematic review and meta-analysis	44
Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models	43
Current status of locally advanced rectal cancer therapy and future prospects	43
Efficacy of PD-1/PD-L1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: A systematic review	43
The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth	42
The BCL-2–tumor microenvironment axis: Mechanisms of immune suppression, resistance, and pathways to therapeutic reprogramming	42
Stereotactic body radiotherapy as an alternative to brachytherapy in cervical cancer (SCORE): A systematic review and meta-analysis	42
Bidirectional role of neutrophils in lung cancer: Mechanisms and therapeutic implications	41
Mapping the research landscape of HPV-positive oropharyngeal cancer: a bibliometric analysis	41
Microbiome dynamics in breast cancer: Mechanisms, therapeutic impacts and research gaps	41
Spatial multiomics of the breast tumour microenvironment: State of the field, advancements and clinical implementation promises	39
Surface-Enhanced Raman Scattering (SERS) combined with machine learning enables accurate diagnosis of cervical cancer: From molecule to cell to tissue level	39
Instruments and scales for the evaluation of acute radiation dermatitis: A systematic review	39
The hidden hand of endoplasmic reticulum stress in anticancer drug resistance	38
Editorial Board	38
Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions	38
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers	38
Editorial Board	37
Comparative analysis of systemic treatment with or without immune checkpoint inhibitors for advanced or recurrent endometrial cancer: A systematic review and meta-analysis of randomized controlled tri	35
Exosomes derived from cancer-associated fibroblasts mediate response to cancer therapy	34
cGAS–STING signaling pathway in urogenital oncology: Regulation, resistance, and routes to response	34
Comment on “The risk of breast cancer and gynecologic malignancies after ovarian stimulation: Meta-analysis of cohort study”	34
Proton beam therapy versus photon therapy for multiple malignancies: An umbrella systematic review and meta-analysis	34
Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology	34
Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology group	32
Androgen receptor as a prognostic biomarker in breast cancer: A systematic review and meta-analysis	32
TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?	32
KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics	31
Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis	31
Optimal treatment strategy for central nervous system non-germinomatous germ cell tumors: A systematic review and meta-analysis	31
Antibody-Drug Conjugates in urothelial, prostate, and renal cell cancers: A review of current and emerging therapies	30
Next-generation immunotherapy in relapsed/refractory multiple myeloma: Strategies to achieve sustained MRD negativity	30
Impact of adding immune checkpoint inhibitors to standard therapies in non-small cell lung cancer: A systematic review of efficacy outcomes	30
The biology and treatment of leiomyosarcomas	29
MAIT Cells in Tumor Contexts: Functional Diversity and Regulatory Hierarchies	29
Trastuzumab deruxtecan: Redefining precision oncology across HER2-driven cancers	29
The critical role of epithelial-mesenchymal transition (EMT) in colorectal cancer progression and therapeutic outcomes	29
The role of GPI-anchored LY6/uPAR family proteins in connecting membrane microdomains with immune regulation and diseases	29
Predictive factors for return to work among cancer survivors in Europe: A systematic review	29
Histopathological ultrastaging of mesocolic lymph nodes after colon cancer resection: A systematic review and meta-analysis	29
Thrombosis and cachexia in cancer: Two partners in crime?	29
Immunotherapy in OSCC: Current trend and challenges	29
Predictive models for immune checkpoint inhibitor response in cancer: A review of current approaches and future directions	29
UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?	28
First-line treatments for advanced or recurrent endometrial cancer: Systematic literature review of clinical evidence	28

Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challenges	28
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements	28
Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for gastric cancer with peritoneal metastases: A systematic review by the PIPAC UK collaborative	28
Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions	28
Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance	28
Efficacy of stereotactic radiosurgery as single or combined therapy for brain metastasis: A systematic review and meta-analysis	27
The peripheral tumor neuro-microenvironment: Deciphering neural landscape and mechanistic insights for therapeutic innovation	27
Unraveling molecular mechanisms of head and neck cancer	27
Editorial Board	27
The safety and effectiveness of hypofractionated radiotherapy for localized prostate cancer: A systematic review and meta-analysis	27
Minimal residual disease testing for classical Hodgkin lymphoma: A comprehensive review	27
Targeted cancer therapy: A comprehensive review of strategies in drug development	27
Liposomal nanocarriers in precision oncology: Advances and prospects	27
The role and clinical significance of tumor-draining lymph nodes in tumor progression and immunotherapy	27
Evaluating quality of life in thoracic malignancy trials: A scoping review on ESMO-MCBS quality of life checklist adherence and concordance with progression-free and overall survival	26
The role of liquid biopsy in epithelial ovarian cancer: State of the art	26
CRISPR-mediated cancer therapies: Approaches to direct tumor targeting	26
Efficacy and safety of targeted therapy and immunotherapy in advanced vulvar squamous cell carcinoma: A scoping review	26
Neoadjuvant therapy in ovarian cancer: Emerging paradigms and therapeutic frontiers	26
Trispecific antibodies: From challenges to integration in cancer therapy	26
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways	26
Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise	25
Challenges facing CAR T-cell immunotherapy in multiple myeloma	25
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors	25
A comprehensive review on targeting diverse immune cells for anticancer therapy: Beyond immune checkpoint inhibitors	25
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review	25
Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management	25
Personalized neoantigen cancer vaccines: Why clinical benefit remains inconsistent	25
The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis	24
Editorial Board	24
Epigenetic mechanisms of PARP inhibitor resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes	24
Application of mRNA Vaccines in Head and Neck Cancer Immunotherapy: Current Progress and Challenges	24
Decoding the puzzle: A multidisciplinary systematic review of adult brainstem glioma	24
RNA N4-acetylcytidine modification in gastrointestinal cancer: Novel functions, mechanisms, and therapeutic implications	24
CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology – A comprehensive analysis of clinical trials	24
Editorial Board	24
Corrigendum to “A review of relative dose intensity and survival in patients with metastatic solid tumors” [Crit. Rev. Oncol. Hematol. 93 (2015) 203–210]	24
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC	23
Epigenetic-modifying agents: The potential game changers in the treatment of hematologic malignancies	23
The novel roles of RNA 5-methylcytosine modification in gastrointestinal tract cancers	23
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors	23
Bridging the translational gap in HNSCC immunotherapy: From resistance mechanisms to high-fidelity preclinical models	23
Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials	23
Rethinking treatment paradigms: Neoadjuvant therapy and de-escalation strategies in HPV-positive head and neck cancer	22
« Augmented radiotherapy » in the management of high-risk prostate cancer (PCa): A systematic review	22
Plasmonic surgery: SERS-active smart nanotools reshaping intraoperative decision-making and precision therapy	22
The pH perspective of cancer: From warburg's misconception to therapeutic targeting of pH regulating proteins	22
Pathology, immunosuppression and NK cell immunotherapy of non-small cell lung cancer	22
Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects	22
Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis	22
Recent development in bispecific antibody immunotherapy for hematological malignancies	22
Targeting TIME in advanced hepatocellular carcinoma: Mechanisms of drug resistance and treatment strategies	22
Strategies to overcome chemoresistance in epithelial ovarian cancer: Navigating beyond challenges	22
Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors	22
Facing the climate change: Is radiotherapy as green as we would like? A systematic review	22
Combining gut microbiota modulation and immunotherapy: A promising approach for treating microsatellite stable colorectal cancer	22
Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering	22
Advances in intravesical therapy for non-muscle-invasive bladder cancer	21
Unlock the code of MHC II-enabled Cancer immunotherapy	21
Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications	21
Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers	21
Salvage radiotherapy after initial cryotherapy for localized prostate cancer: A systematic review of the literature	21
Recent advances and research progress in biomarkers for chronic graft versus host disease	21
NRG1 fusions：The potential targeted treatment in non-small cell lung cancer(NSCLC)	21
Sialylated glycoproteins and sialyltransferases in digestive cancers: Mechanisms, diagnostic biomarkers, and therapeutic targets	21
Advancing CAR-T cell manufacturing in Latin America: Current landscape, future directions, and challenges	20
Microbiota and esophageal cancer: From dysbiosis to carcinogenesis	20
The impact of survivorship bias in glioblastoma research	20
Artificial intelligence in NSCLC management for revolutionizing diagnosis, prognosis, and treatment optimization: A systematic review	20
Cardio-oncology concerns in radiotherapy: Heart and cardiac substructure toxicities from modern delivery techniques	20
Shaping immunotherapy through the tumor microenvironment: Translational perspectives	20
Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma	20
The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma – A review of the literature	20
Next-Generation models of Gallbladder Carcinoma: Linking biological insights to precision medicine	20
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis	20
Is it a new era for intrahepatic cholangiocarcinoma?	19
Anticancer mechanisms and applications based on γδ T cells in cancer immunotherapy	19
Current landscape of hypoxia in thyroid cancer pathogenesis and treatment	19
Biomarkers in blood and saliva to screen fragile patients with solid tumors: A systematic review of the literature	19
Elucidating the mechanistic role of ovarian cancer biomarkers: Lessons learnt from affinity-proteomics	19

Symptomatologic outcomes of gut microbiota modifiers (probiotics, prebiotics and synbiotics) in cancer care: A scoping review of randomized controlled trials	19
Testicular germ cell tumors: Genomic alternations and RAS-dependent signaling	19
Co-localization analysis of spatial transcriptomics in ligand-receptor pairs from tumor microenvironment	19
The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis	19
Rare histotypes of epithelial biliary tract tumors: A literature review	19
Molecular oncology of iodine refractory thyroid cancer current therapies and perspective	19
Radiotherapy of high-grade gliomas: dealing with a stalemate	19
IHC-based molecular classification in muscle-invasive urothelial bladder carcinoma: Prognostic and predictive value toward a clinically applicable IHC marker panel – A systematic review	19
Chemoimmunotherapy efficacy in patients with and without liver metastases: A systematic review and meta-analysis	19
Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to lymphoma	19
Targeting breast cancer stem cells through retinoids: A new hope for treatment	19
Molecular mechanisms of ferroptosis and its role in prostate cancer therapy	19
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group	19
The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis	19
Prognostic value of CD49d in CLL: Systematic review and meta-analysis	19
Uncovering the bookshelves of CRISPR-based libraries: Advances and applications in cancer studies	19
Multidisciplinary therapy managements in endometrial and renal cancer patients treated with pembrolizumab and lenvatinib: a virtuous circle between oncologists and organ specialists	19
Circular RNAs: A key modulator of established cancer hallmarks	19
N6-methyladenosine-dependent signaling in colorectal cancer: Functions and clinical potential	19
Circular RNAs as key regulators in cancer hallmarks: New progress and therapeutic opportunities	18
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer	18
Radiosensitization strategies for hepatocellular carcinoma: Mechanisms, therapeutic advances, and clinical perspectives	18
Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients	18
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach	18
Immune checkpoint inhibitors as a threat to reproductive function: A systematic review	18
The diagnostic accuracy of single-item scales in detecting fatigue in patients with cancer: A systematic review and meta-analysis	18
Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress	18
Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options	18
The educational contribution of the college of the European school of oncology (ESCO): A survey analysis of the first three years	18
Role of innate immunity in tumor microenvironment of HPV-associated anal cancer: The hypothetical beneficial role of γδ T cells.	18
Evaluation of clinical decision support systems in oncology: An updated systematic review	18
Incidence of antibody–drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis	18
Deciphering the possible reciprocal loop between hepatic stellate cells and cancer cells in the tumor microenvironment of the liver	18
Editorial Board	18
Editorial Board	18
Effect of non-pharmacological interventions on symptoms and quality of life in patients with hematological malignancies – A systematic review	17
TRAIL-functionalized nanoparticles in cancer therapy: Molecular mechanisms and translational opportunities	17
Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review	17
Pseudogenes in breast cancer pathogenesis and their clinical utility	17
Radioprotective agents against the ionizing radiation-induced hematopoietic stem and progenitor cell injury; Foundation review	17
A neuroendocrine biomarker revolution from monoanalyte to multianalyte biomarkers in non-functioning gastro-entero-pancreatic neuroendocrine neoplasms	17
Novel insights into UDP-glucuronosyltransferase 1A1 dysfunction and Gilbert’s syndrome on estrogen metabolism and breast cancer	17
Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments	17
The role of the SIX family in cancer development and therapy: Insights from foundational and cutting-edge research	17
Immunotherapy failure in glioblastoma: A systematic review and meta-analysis of randomized controlled trials	17
The influence of genetic variation on late effects in childhood cancer survivors: An updated systematic review	17
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I	17
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis	17
The roles of immune cells and non-immune cells in pre-metastatic niche of breast cancer	17
Chimeric antigen receptor T cell immunotherapy for gynecological malignancies	17
Additions and subtractions of radiotherapy in patients with oligometastatic non-small cell lung cancer under the era of immunotherapy	17
mRNA vaccines in gastrointestinal cancers: Mechanistic basis, translational challenges, and emerging therapeutic strategies	17
Significance of HOXD transcription factors family in progression, migration and angiogenesis of cancer	17
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer	16
Venetoclax and ibrutinib: Two partners for the front-line treatment of chronic lymphocytic leukemia	16
Extrachromosomal DNA in cancer: Molecular mechanisms underlying oncogene amplification and tumor heterogeneity	16
Safety assessment of antibody-drug conjugates: Nonclinical toxicology, non-active ingredients, and environmental risk considerations	16
Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis	16
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)	16
Spread through air spaces in lung cancer: From controversy to consensus	16
Status of breast cancer in Latin American: Results of the breast cancer revealed initiative	16
Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review	16
The application of stepped-wedge cluster-randomized controlled trial study designs in oncology settings: A systematic review	16
Stereotactic body radiotherapy boost as an alternative to brachytherapy for cervical cancer: A scoping review	16
Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review	16
Prognostic impact of CT-defined sarcopenia and prognostic nutritional index in immune checkpoint inhibitor–treated head and neck squamous cell carcinoma: A systematic review and meta-analysis	16
Polyploid giant cancer cells: Underlying mechanisms, signaling pathways, and therapeutic strategies	16
Dynamic interplay of neuroendocrine signaling and immuno-surveillance in tumor niche remodeling	16
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives	16
Non-coding RNAs and liquid biopsies: Emerging biomarkers for cervical cancer	16
Spatial transcriptomics in pancreatic cancer: Advances, prospects and challenges	16
Epigenetics in advanced renal cell carcinoma: Potential new targets	15
Advancing patient setup: A comprehensive scoping review of tattoo-less techniques in radiation therapy	15
Targeting metabolic reprogramming in multiple myeloma: Molecular mechanisms and potential therapeutic targets	15
WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials	15
Fatty acid in the tumor microenvironment: Perspectives for immunotherapy	15
Venous thromboembolism in cancer and cancer immunotherapy	15
Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis	15
Long non-coding RNAs as immune landscape regulators in cancer: A spotlight on HEIH in immuno-oncology	15
Harnessing synergy: Innovative combinations to overcome PARP inhibitor resistance in cancer treatment	15
Metaplastic breast cancer: A review	15
Exploring the molecular interactions between ferroptosis and the Wnt/β-catenin signaling pathway: Implications for cancer and disease therapy	15
The gut-tumor metabolic axis: A comprehensive exploration of bidirectional crosstalk in cancer immunotherapy	15
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic st	15
Cardiac and vascular toxicity of amivantamab in non-small cell lung cancer (NSCLC): A systematic review	15
Comment on “A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma”	15
Erratum to “Beyond the blood-brain barrier: Intranasal vaccines in cancer immunotherapy” [Crit. Rev. Oncol./Hematol. 216C (2025) 104938]	15
Neural stem cells and glioblastoma stem cells: Redefining concepts	15
Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications	15
Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations	15
Corrigendum to “Updated review on analysis of long non-coding RNAs as emerging diagnostic and therapeutic targets in prostate cancers” [Crit. Rev. Oncol./Hematol. 196 (2024) 104275]	14
From diagnosis and treatment to prognosis: Clinical prospects of artificial intelligence in multimodal research of hepatocellular carcinoma	14
Patients’ selection and trial matching in early-phase oncology clinical trials	14
How safe and effective is irradiating radiation-induced meningiomas? Single-center experience in primary and salvage Gamma-Knife Radiosurgery, systematic review, and metanalysis of current evidence on	14
International consensus on the initial diagnostic workup of cancer of unknown primary	14